In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront

Lei Lei Wu

News Reporter

Takeda is buying Nimbus’ late-stage TYK2 inhibitor, an oral drug for autoimmune diseases, for $4 billion in cash upfront. That sets Takeda up to compete …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

In its largest sin­gle-as­set pur­chase ever, Take­da snaps up TYK2 drug for $4B up­front

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

In its largest single-asset purchase ever, Takeda snaps up TYK2 drug for $4B upfront